BioNTech SE (NASDAQ:BNTX) Given Average Recommendation of “Hold” by Brokerages

BioNTech SE (NASDAQ:BNTX) has received a consensus rating of “Hold” from the ten ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $111.70.

Several research analysts recently commented on the company. JPMorgan Chase & Co. reduced their price target on BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a research report on Friday, March 22nd. Canaccord Genuity Group reissued a “buy” rating and set a $171.00 price target on shares of BioNTech in a research report on Thursday, March 21st. HC Wainwright reissued a “buy” rating and set a $113.00 price target on shares of BioNTech in a research report on Wednesday, June 26th. TD Cowen increased their price target on BioNTech from $95.00 to $98.00 and gave the company a “hold” rating in a research report on Tuesday, May 7th. Finally, BMO Capital Markets reduced their price target on BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a research report on Tuesday, May 7th.

BioNTech Stock Up 1.4 %

NASDAQ:BNTX opened at $79.86 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38. The company has a market cap of $18.99 billion, a PE ratio of 159.72 and a beta of 0.23. BioNTech has a 52-week low of $78.02 and a 52-week high of $125.83. The stock has a 50-day simple moving average of $91.54 and a 200 day simple moving average of $94.11.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, May 6th. The company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.60). BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The company had revenue of $203.69 million for the quarter, compared to analyst estimates of $589.96 million. On average, sell-side analysts expect that BioNTech will post -2 EPS for the current fiscal year.

Institutional Trading of BioNTech

Several hedge funds have recently added to or reduced their stakes in BNTX. Harding Loevner LP acquired a new stake in BioNTech during the 4th quarter worth approximately $410,984,000. Primecap Management Co. CA lifted its holdings in BioNTech by 2.8% during the 4th quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock worth $502,735,000 after purchasing an additional 131,490 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in BioNTech by 43.1% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 425,071 shares of the company’s stock worth $44,610,000 after purchasing an additional 127,951 shares during the last quarter. abrdn plc acquired a new stake in BioNTech during the 4th quarter worth approximately $10,961,000. Finally, Baillie Gifford & Co. lifted its holdings in BioNTech by 1.0% during the 4th quarter. Baillie Gifford & Co. now owns 8,689,182 shares of the company’s stock worth $917,056,000 after purchasing an additional 86,343 shares during the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.